The top dog in river cruises is trouncing the market, unlike the three better-known traditional cruise line operators.

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.18, moving +1.64% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.58%. Meanwhile, the Dow ...

From late 2023 to early 2024, Viking Therapeutics (NASDAQ: VKTX) took off like a rocket, as it seemed that the clinical-stage ...

There's a lot on the minds of Viking Holdings (NYSE: VIK) shareholders heading into this week's financial update. Unlike the ...

Biotech company Viking Therapeutics has emerged as a strong potential player — and deal target — in the budding weight loss drug market. Viking is just one of several companies racing to join the ...

So first, let's consider Viking's story so far. The company is working on a dual GLP-1/GIP receptor agonist in injectable and oral formats. Injectable VK2735 is involved in a phase 3 trial right now, ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...

Viking Moorings announced the appointment of Bill Bayliss as Group Chief Executive, heralding a significant restructuring of the company, which involved the co-existing shareholders. Bayliss, who is ...